JOINTOWN PHARMACEUTICAL GROUP Sustainability Profile
JOINTOWN PHARMACEUTICAL GROUP, a leading player in the pharmaceutical industry, is headquartered in China and operates extensively across various regions. Founded in 1995, the company has established itself as a key provider of high-quality pharmaceutical products and services, focusing on areas such as drug distribution, manufacturing, and research and development. With a diverse portfolio that includes prescription medications, over-the-counter products, and healthcare services, JOINTOWN is recognised for its commitment to innovation and quality. The company has achieved significant milestones, including strategic partnerships and expansions that enhance its market position. JOINTOWN PHARMACEUTICAL GROUP continues to set industry standards, making it a trusted name in healthcare solutions.
DitchCarbon Score
How does JOINTOWN PHARMACEUTICAL GROUP's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
JOINTOWN PHARMACEUTICAL GROUP's score of 24 is lower than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
JOINTOWN PHARMACEUTICAL GROUP's reported carbon emissions
In 2024, JOINTOWN PHARMACEUTICAL GROUP reported total carbon emissions of approximately 36,924,210 kg CO2e for Scope 1 and about 11,005,200 kg CO2e for Scope 2, resulting in a combined total of around 47,929,410 kg CO2e. This data reflects the company's commitment to transparency in its emissions reporting. In 2023, the company recorded Scope 1 emissions of approximately 318,939,120 kg CO2e, with specific contributions from mobile combustion (about 2,405,420 kg CO2e) and stationary combustion (approximately 4,334,300 kg CO2e). Notably, JOINTOWN PHARMACEUTICAL GROUP has not disclosed any Scope 3 emissions data. Despite the significant emissions figures, the company has not set specific reduction targets or initiatives, nor does it participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). The absence of reduction commitments indicates a potential area for improvement in their climate strategy. Overall, JOINTOWN PHARMACEUTICAL GROUP's emissions data highlights the need for enhanced climate action and transparency in their environmental commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 318,939,120 | 00,000,000 |
| Scope 2 | - | 00,000,000 |
| Scope 3 | - | - |
How Carbon Intensive is JOINTOWN PHARMACEUTICAL GROUP's Industry?
How Carbon Intensive is JOINTOWN PHARMACEUTICAL GROUP's Location?
JOINTOWN PHARMACEUTICAL GROUP's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
JOINTOWN PHARMACEUTICAL GROUP has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
